Lishengpharma(SZ:002393) Quan Jing Wang·2025-06-09 04:25Core Viewpoint - The company is actively enhancing its market value through various strategies, including mergers and acquisitions, value management tools, and consistent cash dividends to shareholders, resulting in a significant increase in market capitalization and stock price [2][4]. Group 1: Value Management and Market Performance - The company has focused on value creation, operational management, communication, and realization to enhance its market value [2]. - The company has acquired Jiangxi Qingshunkangyuan Pharmaceutical and established an industrial fund, which has contributed to revitalizing underperforming assets [2]. - From early April to the end of May, the company's market value increased by over 13%, and as of June 4, the stock price reached a six-year high [2]. Group 2: Strategic Focus and Industry Positioning - The company is concentrating on its core business and optimizing its industrial layout, with a dual-driven development model of "industry + capital" [3]. - The company is committed to enhancing its core competitiveness and has developed a systematic plan to improve the quality of the listed company [3]. Group 3: Innovation and R&D Investments - The company is actively engaged in innovative drug research and development, employing a strategy of "internal growth and external introduction" [4][9]. - In 2024, the company's R&D investment reached 127 million yuan, a year-on-year increase of 21.56%, with the number of R&D personnel rising to 354 [4]. - The company has achieved drug registration certificates for high-end generic drugs and is collaborating with the Chinese Academy of Sciences on projects in synthetic biology [4][9]. Group 4: Financial Management and Shareholder Returns - The company distributed 89.69 million yuan in dividends for the 2024 fiscal year and is open to mid-year dividend announcements based on performance [6][11]. - The company has a cash reserve of 1.9 billion yuan and is utilizing idle funds for stable financial investments while planning for strategic investments and new product development [7][10]. - The company completed a stock buyback from December 25, 2024, to January 9, 2025, repurchasing 7,209,980 shares, which is 2.80% of the total share capital [12][20].